May 14, 2015- By Steven E. Greer, MD
Stroke is the bane of TAVR. In the Edwards Lifesciences Sapien valve, stroke rates exceed 10%. That, along with perivalvular leaks, resulted in death rates of 30% at two-years. Read more »
November 13, 2013- By Steven E. Greer, MD
The AHA released the long-awaited new guidelines that recommend which patients should be on a cholesterol-lowering statin, such as Lipitor or Crestor. The panel of experts incorporated evidence-based medicine into the guidelines, perhaps better than any other medical society guideline panel has done previously. However, the panel also used some very dubious statistical tools as well.
According to Read more »
June 15, 2014- By Steven E. Greer, MD
34-year-old Erik Compton finished tied for second in the United States Open golf tournament. That was a good accomplishment by any standard, but it was also a genuine feat of modern medicine and surgery because he is living on his third heart. Read more »
March 23, 2014- interviewed by Steven E. Greer, MD
With catheter based methods for replacing the aorta valve not being adopted as expected, the medical device industry is now looking to the mitral valve for hope. Doctors in London and Canada performed Read more »
July 5, 2015- Interviewed by Steven E. Greer, MD
We interviewed William Suh, MD of UCLA about the newly approved Edwards Lifesciences Sapien 3 aortic valve. Read more »
May 7, 2015- Interviewed by Steven E. Greer, MD
April 21, 2015- By Steven E. Greer, MD
Brigham and Women’s Hospital in Boston, part of the Harvard University network of hospitals, has begun a rather perplexing public relations campaign. On national TV shows, such as PBS’ Frontline, Read more »
March 18, 2015- Op-Ed by Steven E. Greer, MD
The American College of Cardiology (ACC) meeting is underway, and the main Late Breaking data making the national news came from the PCSK9-antibody drugs (evolocumab and alirocumab) that dramatically Read more »
March 23, 2015- Interviewed by Steven E. Greer, MD
We interviewed the Principal Investigator of the PROMISE trial, Pamela Douglas, MD from Duke. Read more »